Celogos has a portfolio of products, focusing on functional repair of damaged muscular tissue.
The company is currently developing two cell therapy products: RCD1 and RCD2.
- RCD-1 is a first generation, cell-based product intended for stress urinary incontinence treatment. Following proof of concept in an animal model, RCD1 been evaluated in two phase II clinical trials with promising results. Celogos believes that, once validated, RCD1 will be well-positioned for approval as a first-line treatment for stress urinary incontinence;
- RCD-2 is indicated for the treatment of anal incontinence; and is currently being evaluated in a phase II clinical trial;
| Research | Preclinical | Phase I | Phase II | Phase III | |
|---|---|---|---|---|---|
| Autologous Products: Cell therapy products focusing on achieving functional repair of damaged muscle tissue |
|||||
| RCD-1 Stress urinary incontinence |
 |
||||
| RCD-2 Anal incontinence |
|
||||
Currently, Celogos develops products in various indications currently at different stages of development (conception of new product, preclinical, clinical development and MA deposition).